Substance / Medication

Sucralfate

Overview

Active Ingredient
sucralfate
RxNorm CUI
10156

Indications

Sucralfate Oral Suspension is indicated in the short-term (up to 8weeks) treatment of active duodenal ulcer.

Labeler: Major PharmaceuticalsUpdated: 2026-02-11T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

24 trials linked to this intervention

24
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The role of postoperative sucralfate in adults following tonsillectomy and sleep surgery: a systematic review.
McCray Lauren R, Briggs Erin E, Patel Jaimin J et al. · Eur Arch Otorhinolaryngol · 2025
PMID: 40155548Meta-AnalysisFull text (PMC)
Topical sucralfate for treatment of mucocutaneous conditions: A systematic review on clinical evidences.
Abtahi-Naeini Bahareh, Saffaei Ali, Sabzghabaee Ali Mohammad et al. · Dermatol Ther · 2022
PMID: 35080090Meta-Analysis
[Effects of sucralfate and acid-suppressive drugs on preventing ventilator- associated pneumonia of mechanically ventilated patients: a meta-analysis].
He Hongli, Hu Shuling, Chen Qihong et al. · Zhonghua Nei Ke Za Zhi · 2014
PMID: 24674729Meta-Analysis
Clinical Trial: Precise Administration of Sucralfate Powder in Prevention of Delayed Postpolypectomy Bleeding. A Randomized Controlled Trial.
Chiang Hsueh-Chien, Chen Po-Jun, Yang Er-Hsiang et al. · Clin Transl Gastroenterol · 2025
PMID: 39836033RCTFull text (PMC)
Topical sucralfate for prevention of peristomal wound reaction related to percutaneous endoscopic gastrostomy in children: A randomized controlled trial.
Saneian Hossein, Mehrannia Atoosa, Sabzghabaee Ali Mohammad et al. · Dermatol Ther · 2022
PMID: 35871473RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sucralfate (substance)
SNOMED CT
387387008
UMLS CUI
C0038633
RxNorm CUI
10156
Labeler
Major Pharmaceuticals

Clinical Data

This intervention maps to 12 entities in the Healos knowledge graph.

7
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
24
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.